Roche plans to invest $50 billion in the US over the next five years. These investments will strengthen the pharmaceutical company's presence in the United States. There it has 13 manufacturing sites and 15 research and development sites for pharmaceuticals and diagnostics. More than 12,000 new jobs are expected to be created. This includes nearly 6,500 in construction and 1,000 in new and expanded facilities. As part of this investment, Roche plans to expand its existing presence at 24 sites in eight US states.
Planned investment projects of Roche
The investment includes the expansion and modernization of production and distribution capacities for the drug and diagnostics portfolio in Kentucky, Indiana, New Jersey, Oregon, and California. In addition, a state-of-the-art production facility for gene therapy will be built in Pennsylvania. In addition, a new 900,000 square foot manufacturing centre is planned to support Roche's growing portfolio of new medicines for weight loss. The location will be announced shortly. Further investments include a new production facility for continuous glucose monitoring in Indiana. A new research and development center for cutting-edge research in artificial intelligence is planned in Massachusetts. This center will serve as a hub for new research and development activities in the cardiovascular, renal, and metabolic areas. Finally, the existing research and development centers for pharmaceuticals and diagnostics in Arizona, Indiana, and California will be significantly expanded and modernized.
Long-term commitment to research, development, and manufacturing in North America
“Roche is a Swiss company with a strong heritage in more than 130 countries globally. Today’s announced investments underscore our long-standing commitment to research, development and manufacturing in the US,” said Thomas Schinecker, Roche Group CEO. “We are proud of our 110 year legacy in the United States which has been a key driver for jobs, innovation and the creation of intellectual property in the US, across both our Pharmaceutical and Diagnostics Divisions. Our investments of $50 billion over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the US and around the world.”
Roche achieves export surplus from the US by expanding production
Once all new and expanded production capacities are up and running, Roche will export more drugs from the US than it imports. The Diagnostics Division already has an export surplus from the US to other countries.
